We analyzed GR/PRMT5 interactions in TNBC PDX models including models engrafted from treatment-naïve patients (primary tumor) and TNBC tumors established from residual tumors after neoadjuvant chemotherapy administered in association with GCs (residual tumors). Here, PRMT5 is linked to neoplasm.